Speak to the pharma team
01628 581 240
Speak to the healthcare team
01225 336 335
Speak to the clinical team
01628 581 240
Speak to the contract team
01225 336 335
Speak to us about Master Vendor
01225 336 335
Or send your enquiry via email and the best person to help will be in touch.
solutions@starmedical.co.uk
Sankyo's predecessor, Sankyo Shoten was established in Japan in 1899. Daiichi established their US subsidiary in New York in 1982. Daiichi and Sankyo integrated to become Daiichi Sankyo in 2006.
Daiichi Sankyo prides themselves on innovation and development in the areas of cardiovascular disease, cancer, diabetic and metabolic disorders, bone/joint disease, immunological/allergic disease and infectious disease, focusing on the Primary Care sector. They discovered epinephrine and developed the statin class of lipid-lowering agents and the first glitazone, revolutionizing the long-term control of type 2 diabetes.
Corporate values include Innovation, Integrity, Collaboration, Respect and Accountability.
